Eledon Pharmaceuticals Inc (ELDN) Stock Price, Quote & News

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 238 8090

Website: eledon.com

Address:

19800 MacArthur Boulevard, Suite 250, Irvine, United States

RNASequencing Aug. 6 at 1:51 AM

$ELDN so did the data leak after hours somewhere?

1 · Reply

theoptionsplug Aug. 5 at 11:18 PM

Things to Watch Wednesday: - Eledon Pharmaceuticals $ELDN will present new clinical results at the World Transplant Congress from its ongoing open-label Phase 1b trial of tegoprubart, aimed at preventing organ rejection in kidney transplant patients 🧫 - Fed Governor Lisa Cook and Boston Fed President Susan Collins will join a panel titled “A Central Bank Perspective on the Evolving Global Landscape.” 🏦 - 8:30AM: McDonald's $MCD will report earnings. Analysts expect insights on consumer behavior that may influence the broader restaurant industry. Lamb Weston $LW, which earns 15% of its revenue from McDonald's and often trades in sync with it post-earnings, will also be under close watch 🍟 - 3:10PM: San Francisco Fed President Mary Daly will speak and take part in a moderated discussion at the 2025 Anchorage Economic Summit 🎙️

0 · Reply

NotoriousBRGX Aug. 5 at 10:04 PM

$ELDN Bought on the recommendation of someone very familiar with the clinical trials This person is very confident in Tegoprubart’s efficacy.

0 · Reply

elmono Aug. 5 at 9:14 PM

$ELDN just so we are all on the same page: from latest Q release: “ Cash, cash equivalents and short-term investments totaled $124.9 million as of March 31, 2025 compared to $140.2 million as of December 31, 2024. The company expects current cash, cash equivalents and short-term investments to fund operations to the end of 2026.” Pretty clear message

0 · Reply

elmono Aug. 5 at 9:13 PM

$ELDN think we found our manipulator 👇

0 · Reply

elmono Aug. 5 at 9:12 PM

$ELDN lost all credibility with that comment 😂👇🤡

0 · Reply

MightyOak Aug. 5 at 6:12 PM

$ELDN Only time will tell! But here’s my hunch: If the news wasn’t good, why accept an invitation to publicly present a failing product? My guess? The oral presentation titled “Tegoprubart, an Anti‑CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study,” featuring data from ~30 kidney transplant patients... probably includes some good news.

2 · Reply

Mdelagar777 Aug. 5 at 4:29 PM

$ELDN I am starting to worry about this stock…looks like a lot of people are abandoning ship before the big news comes out tomorrow. If anyone has any positive news to share about Eledon, please let me know. Would be very appreciated

1 · Reply

SlayQueenOfCalls Aug. 4 at 6:07 PM

Thank you $ELDN

1 · Reply

SlayQueenOfCalls Aug. 4 at 6:00 PM

$ELDN anyone else just see that? Calls volume jump?? Anyone 😭😭 I hate when I get greedy and wish I got more. Where my “penny for a pound” guy at? (THANK YOU)!

0 · Reply

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 19 days ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jun 25, 2025, 4:01 PM EDT - 5 weeks ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 2 months ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 6, 2025, 1:15 PM EDT - 3 months ago

Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +

GEVO IRDM LPG

May 3, 2025, 8:15 AM EDT - 3 months ago

Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet

Mar 20, 2025, 4:01 PM EDT - 4 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 4, 2025, 4:05 PM EST - 5 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 6 months ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Jan 29, 2025, 4:05 PM EST - 6 months ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 28, 2025, 11:27 AM EST - 6 months ago

Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business

Jan 13, 2025, 7:00 AM EST - 7 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 12, 2024, 4:01 PM EST - 9 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Oct 29, 2024, 3:51 PM EDT - 10 months ago

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29, 2024, 7:46 AM EDT - 10 months ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 10 months ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 11, 2024, 4:05 PM EDT - 11 months ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 11 months ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 3, 2024, 4:01 PM EDT - 1 year ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

May 9, 2024, 7:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 1 year ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 25, 2024, 4:56 PM EDT - 1 year ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 1 year ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024, 4:40 PM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Nov 29, 2023, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 9, 2023, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 8, 2023, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 2, 2023, 9:05 AM EDT - 1 year ago

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Oct 23, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Oct 13, 2023, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Oct 2, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Sep 20, 2023, 4:05 PM EDT - 2 years ago

Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

May 12, 2023, 1:03 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Earnings Call Transcript

May 10, 2023, 2:45 PM EDT - 2 years ago

Eledon Pharmaceuticals: Disrupting The Kidney Transplantation Landscape

Mar 31, 2023, 6:00 AM EDT - 2 years ago

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

Mar 30, 2023, 8:28 PM EDT - 2 years ago

Eledon Pharmaceuticals, Inc. (ELDN) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

Mar 23, 2023, 4:05 PM EDT - 2 years ago

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

Feb 8, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

RNASequencing Aug. 6 at 1:51 AM

$ELDN so did the data leak after hours somewhere?

1 · Reply

theoptionsplug Aug. 5 at 11:18 PM

0 · Reply

NotoriousBRGX Aug. 5 at 10:04 PM

$ELDN Bought on the recommendation of someone very familiar with the clinical trials This person is very confident in Tegoprubart’s efficacy.

0 · Reply

elmono Aug. 5 at 9:14 PM

0 · Reply

elmono Aug. 5 at 9:13 PM

$ELDN think we found our manipulator 👇

0 · Reply

elmono Aug. 5 at 9:12 PM

$ELDN lost all credibility with that comment 😂👇🤡

0 · Reply

MightyOak Aug. 5 at 6:12 PM

2 · Reply

Mdelagar777 Aug. 5 at 4:29 PM

1 · Reply

SlayQueenOfCalls Aug. 4 at 6:07 PM

Thank you $ELDN

1 · Reply

SlayQueenOfCalls Aug. 4 at 6:00 PM

$ELDN anyone else just see that? Calls volume jump?? Anyone 😭😭 I hate when I get greedy and wish I got more. Where my “penny for a pound” guy at? (THANK YOU)!

0 · Reply

SlayQueenOfCalls Aug. 4 at 5:27 PM

$ELDN people holding on to their calls.. this one reminds me of $RDW back in November.. like only few know and you’re lucky if you can get in but expensive…

0 · Reply

Ontherag Aug. 4 at 3:21 PM

$ELDN Almost 600k volume

1 · Reply

ErnieWorthing84 Aug. 3 at 9:34 PM

$ELDN

1 · Reply

MrCodyHUN Aug. 3 at 12:55 PM

$ELDN Pretty excited for next week

0 · Reply

RNASequencing Aug. 2 at 1:14 AM

$ELDN this has a shot still. Taking a position might take it on the chin but phase1b and November phase2 will be telling on future for this company. Good luck to the bulls and bears

0 · Reply

ErnieWorthing84 Aug. 1 at 8:21 PM

$ELDN Apparently the case was reported to the BESTOW Data Safety Monitoring Board (DSMB) as being non-drug-related

0 · Reply

jshlam Aug. 1 at 6:50 PM

$ELDN bump

0 · Reply

ErnieWorthing84 Aug. 1 at 4:46 PM

$ELDN

1 · Reply

jshlam Aug. 1 at 3:50 PM

$ELDN 6th should be strong fingers crossed

0 · Reply

SlayQueenOfCalls Aug. 1 at 2:40 PM

$ELDN it does! Haha we need more ppl to celebrate with though.. our community is strong but sparse

2 · Reply

FelixH86 Jul. 31 at 6:09 PM

$ELDN looks good..

0 · Reply

Channelchek Jul. 31 at 3:51 PM

Noble Capital Markets Research Report: Eledon Pharmaceuticals ($ELDN) – Abstract From A Single Patient Is Not A Safety Concern We Look Forward To Data At The World Transplant Congress. Eledon is scheduled to present interim data from its Phase 1b study at the World Transplant Congress (WTC), to be held August 2 to 6. We have also seen an abstract discussing a single patient in the Phase 2 BESTOW trial that had an unrelated fungal infection. While we do not consider the abstract to be significant, it may have raised safety concerns for investors. Read more: https://www.channelchek.com/news-channel/eledon-pharmaceuticals-eldn-abstract-from-a-single-patient-is-not-a-safety-concern

0 · Reply

Market Cap	194.62M
Revenue (ttm)	0.00
Net Income (ttm)	-36.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,102,600
Avg Vol	623,544
Day's Range	N/A - N/A
Shares Out	59.88M
Stochastic %K	22%
Beta	-0.15
Analysts	Strong Sell
Price Target	$9.50